-
Dec 05 |
Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.
More
-
Nov 30 |
Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.
More
-
Nov 29 |
Diagnostics World | Illumina enters a multi-year agreement with Veracyte to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument; Boston Scientific Corporation acquires Relievant Medsystems to add to chronic pain portfolio; Oxford Nanopore Technologies and Fabric Genomics collaborate to develop a software solution analysis and clinical reporting of rich genomic data for faster insights to support rapid disease characterization of babies and children with genetic disorders in acute settings; more.
More
-
Nov 28 |
Diagnostics World | Investigators at Cedars-Sinai Medical Center are looking to minimize the biases in the data used by artificial intelligence (AI) algorithms, most recently a deep learning model trained on nearly a million electrocardiograms (ECGs) to identify people with abnormal heart rhythms.
More
-
Nov 21 |
Diagnostics World | Cystic fibrosis (CF) is one of the few genetic disorders to be considered both serious and common enough to merit universal carrier or prenatal screening. Unfortunately, though, current testing approaches are caught between evolution and revolution even as they continue to produce suboptimal results for people of non-European ancestry.
More
-
Nov 16 |
Diagnostics World | Illumina announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available, or to complement tissue-based testing.
More
-
Nov 15 |
Diagnostics World | The “power of the team approach” was on full display for a study designed to understand the contribution of asymptomatic carriers to the spread of Clostridioides difficile in hospitals.
More
-
Nov 13 |
Bio-IT World | Illumina has launched the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs) and reduced prices.
More
-
Nov 08 |
Diagnostics World | It may be possible one day soon to prevent Alzheimer’s disease, a devastating illness currently suffered by more than 30 million people worldwide. The good news comes straight from the mouth of Randall J. Bateman, M.D., professor of neurology at Washington University School of Medicine and director of the Dominantly Inherited Alzheimer Network (DIAN) and DIAN Trials Unit (DIAN-TU).
More
-
Nov 07 |
Diagnostics World | Mayo Clinic and Oxford Nanopore Technologies teams up in a multi-year joint development collaboration to help improve patient care, including some of the hardest-to-characterize conditions and sequencing DNA; Walgreens and the Cardiovascular Research Foundation (CRF) collaborates to drive the PREVUE-VALVE study, which will help pave the way for the development of new therapies and tools for VHD detection and diagnosis; Genialis announces a new data-sharing collaboration with Cancer Research Horizons to better predict responses to KRAS inhibitors, immunotherapies, and other emerging classes of therapeutics; and more.
More
-
Dec 05 |
VERICHEM offers calibration verification materials for the testing of both urine and serum Magnesium assays.
More
-
Dec 04 |
Dear Nicole,
Biotium, a leading provider of innovative solutions for life science research, has announced the launch of Biotium Choice primary antibody conjugates. With careful curation and extensive in-house validation, Biotium Choice monoclonal primary antibodies are designed to deliver exceptional performance for flow cytometry.
The release of the Biotium Choice primary antibodies adds to Biotium’s growing catalog of robust and validated probes for life science research.
More
-
Dec 01 |
PathAI, a leading digital and computational pathology company which provides precision pathology solutions has announced the availability of ArtifactDetect on AISight™, PathAI’s digital pathology image management system. This product automates the detection of artifacts on digital pathology whole slide images and quantifies the extent of artifact on any WSI.
More
-
Dec 01 |
WCG's IRB+ service has been pressure tested on 90+ studies, ensuring that it maintains the integrity and quality of board reviews while accelerating operational processing, allowing for faster site activation and study start-up.
More
-
Nov 30 |
More
-
Nov 30 |
More
-
Nov 30 |
More
-
Nov 29 |
Eremid® Genomic Services, LLC (“Eremid”) announces its College of American Pathologists (CAP) accreditation, complementing its November 2022 CLIA certification. This landmark demonstrates Eremid’s commitment to meeting and exceeding regulatory standards, proving its ability to provide quality and precision in clinical genomics. This noteworthy development cements Eremid as a trusted partner for end-to-end clinical genomics support capable of delivering high quality test results.
More
-
Nov 29 |
Exothera has announced its Nucleic Acids Chief Technology Officer, Patrick Thiaville has been nominated as a member of the Alliance for mRNA Medicines (AMM) board.
More
-
Nov 28 |
More
View more articles